ReviewImmunological reviews2012
Janus-like effects of type I interferon in autoimmune diseases.
Review in Immunological reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Trial
- Breaking down the cellular responses to type I interferon neurotoxicity in the brain.Frontiers in immunology · 2023Review
- The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement.Frontiers in neurology · 2022Review
- Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE.Scientific reports · 2021Article
- Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice.Science advances · 2021Article
- Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.Clinical reviews in allergy & immunology · 2020Review
- Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica.Nature communications · 2020Article
- Rapid expansion of Treg cells protects from collateral colitis following a viral trigger.Nature communications · 2020Article
- Tolerizing Strategies for the Treatment of Autoimmune Diseases: FromFrontiers in immunology · 2020Review
- Effector T Cells in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2018Review
- Article
- Gene expression profiling offers insights into the role of innate immune signaling in SSc.Seminars in immunopathology · 2015Review
- Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.International journal of molecular sciences · 2015Article
- Type I IFN family members: similarity, differences and interaction.Cytokine & growth factor reviews · 2015Review
- Up-regulation of Kv1.3 channels by janus kinase 2.The Journal of membrane biology · 2015Article
- p204-Mediated innate antiviral responses in mouse adipose cells and their effects on cell functions.Immunology and cell biology · 2015Article
- Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease.The Journal of experimental medicine · 2014Article
- Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis.PLoS pathogens · 2014Article
- Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types.Frontiers in immunology · 2014Review
- Role of microglia in CNS autoimmunity.Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30-50% of MS patients are non-responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.